Month: September 2025

Hong Kong, Sept. 03, 2025 (GLOBE NEWSWIRE) — BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established  meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the partial exercise of the over-allotment option (the “Over-Allotment”) by the underwriter (the “Underwriter”) of its initial public offering (the “Offering”) to purchase an additional 175,000 Class A ordinary shares (the “Class A Ordinary Shares”) of the Company at the public offering price of US$4.00 per share and the closing of such issuance. The Class A Ordinary Shares commenced trading on the Nasdaq Capital Market on August 14, 2025, under the symbol “BUUU.” The Company received aggregate gross proceeds of US$700,000 from this Over-Allotment closing, and the aggregate gross proceeds from the Offering...

Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight® Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual (TAU). Specifically, compared to TAU, patients in the GeneSight arm were:41% more likely to achieve remission. 30% more likely to achieve response.“This meta-analysis summarizes the clinical evidence of the GeneSight test, demonstrating...

ATLANTA, GA., Sept. 03, 2025 (GLOBE NEWSWIRE) — Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced that its Board of Directors has declared a dividend of $0.23 per share for the third quarter of 2025, payable to holders of the Company’s common stock. This is consistent with the dividend for the second quarter of 2025 and reflects an increase of 5% from the prior year. The dividend will be payable in cash on October 15, 2025 to stockholders of record at the close of business on September 30, 2025. About Americold Realty Trust, Inc. Americold (NYSE: COLD) is a global leader in temperature-controlled logistics and real estate, with a more...

DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) —  374Water Inc. (NASDAQ: SCWO) (“374Water” or the “Company”), a global leader in organic waste destruction technology and services for the municipal, federal, and industrial markets, today announced recent open-market stock purchases by Company insiders, including Board members and senior management. 374Water President and CEO Chris Gannon, said, “These share purchases underscore our confidence in 374Water’s vision and the tremendous opportunities ahead for our AirSCWO (“AS”) technology. We believe there is a significant disconnect between our current price and the value we can deliver in the coming years. We have made considerable progress and expect continued advances for our AS technology with ongoing system deployments. With the completion of numerous municipal, federal,...

Third $100M share repurchase authorization announced since November 2023 PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — Upwork Inc. (Nasdaq: UPWK), the world’s human and AI-powered work marketplace, today announced that its board of directors approved an additional $100 million share repurchase program. “Upwork’s financial results continue to exceed expectations, giving us another opportunity to utilize our balance sheet to increase shareholder value,” said Hayden Brown, president and CEO, Upwork. “Our track record of operational discipline and rapid execution is enabling us to grow GSV and continue our market share gains.” Repurchases of Upwork’s common stock under the repurchase authorization may be made from time to time on the open market (including through the use of trading plans intended to qualify under Rule 10b5-1...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor conference. H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 Surrozen presentation will be from 8:30 – 9:00 AM Pacific Time/11:30 –12N Eastern Time Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A replay of the webcast will be archived on the website at www.surrozen.com. About Surrozen  Surrozen is a biotechnology...

WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus. TVGN 489, the Company’s investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy is developed using the ExacTcell platform. It is designed to fortify anti-SARS-CoV-2 immunity in these individuals and directly eliminate the virus. The CTLs are directed against the entire viral genome rather than single protein. Publication of positive POC/dose finding clinical trial data of TVGN 489 is available through Blood Advances: Clinical Trial Key Findings:The treatment arm, which included high-risk patients and half of...

Ra’anana, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, today announced that it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until March 2, 2026 to regain compliance with Nasdaq’s minimum bid price rule. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and...

HIGHLIGHTSA maiden reverse circulation (RC) drilling program is underway at Sherlock Crossing in the West Pilbara, testing high-grade Au-Sb mineralisation at the historic Clarke Mine. The drill program consists of 8 holes on 4 sections for ~1,000 m RC over a strike length of 300 m. Drilling aims to define down dip continuity of high-grade veins mapped at surface, to extend mineralisation to the north and south and to potentially define plunge of the mineralising system. RC drilling is anticipated to be completed in September with results expected in mid-October 2025. At the Wyloo Project in the South Pilbara, mapping and sampling confirmed coherent Sb-Ag-Au anomalism in readiness for drilling. Peak results from rock chip sampling of the polymetallic vein-style mineralisation include 482 g/t Ag, 1.29% Sb, 0.93 g/t Au, 2.6% Cu, 9.7% Pb...

New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions, and elevate sleep as a global health priority. The announcement comes ahead of the World Sleep Congress, taking place September 5–10 in Singapore. Sleep disorders are among...